The
heparan sulfate (HS)
proteoglycan,
syndecan-1, plays a major role in
multiple myeloma (MM) by concentrating
heparin-binding
growth factors on the surface of MM cells (MMCs). Using Affymetrix microarrays and real-time
reverse transcriptase-polymerase chain reaction (RT-PCR), we show that the gene encoding
heparanase (HPSE), an
enzyme that cleaves HS chains, is expressed by 11 of 19 myeloma cell lines (HMCLs). In HSPE(pos) HMCLs,
syndecan-1 gene expression and production of soluble
syndecan-1, unlike expression of membrane
syndecan-1, were significantly increased. Knockdown of HPSE by
siRNA resulted in a decrease of
syndecan-1 gene expression and soluble
syndecan-1 production without affecting membrane
syndecan-1 expression. Thus, HPSE influences expression and shedding of
syndecan-1. Contrary to HMCLs, HPSE is expressed in only 4 of 39 primary MMC samples, whereas it is expressed in 36 of 39 bone marrow (BM) microenvironment samples. In the latter, HPSE is expressed at a median level in polymorphonuclear cells and T cells; it is highly expressed in monocytes and osteoclasts. Affymetrix data were validated at the
protein level, both on HMCLs and patient samples. We report for the first time that a gene's expression mainly in the BM environment (ie, HSPE) is associated with a shorter event-free survival of patients with newly diagnosed myeloma treated with high-dose
chemotherapy and
stem cell transplantation. Our study suggests that clinical inhibitors of HPSE could be beneficial for patients with MM.